Genetic and Microenvironment Features Do Not Distinguish Follicular Lymphoma Patients Requiring Immediate or Deferred Treatment

Wendy B. C. Stevens; G. Tjitske Los-de Vries; Carole Langois-Jacques; Andrew J. Clear; Phylicia Stathi; Birgitta Sander; Andreas Rosenwald; Maria Calaminici; Eva Hoster; Wolfgang Hiddemann; Philippe Gaulard; Gilles Salles; Wolfram Klapper; Luc Xerri; Catherine Burton; Reuben M. Tooze; Alexandra G. Smith; Christian Buske; David W. Scott; Yasodha Natkunam; Ranjana Advani; Laurie H. Sehn; John Raemaekers; John Gribben; Sandra Lockmer; Eva Kimby; Marie José Kersten; Delphine Maucort-Boulch; Bauke Ylstra; Erik van Dijk; Daphne de Jong

doi:https://doi.org/10.1097/HS9.0000000000000863

Genetic and Microenvironment Features Do Not Distinguish Follicular Lymphoma Patients Requiring Immediate or Deferred Treatment

Wendy B. C. Stevens, G. Tjitske Los-de Vries, Carole Langois-Jacques, Andrew J. Clear, Phylicia Stathi, Birgitta Sander, Andreas Rosenwald, Maria Calaminici, Eva Hoster, Wolfgang Hiddemann, Philippe Gaulard, Gilles Salles, Wolfram Klapper, Luc Xerri, Catherine Burton, Reuben M. Tooze, Alexandra G. Smith, Christian Buske, David W. Scott, Yasodha NatkunamRanjana Advani, Laurie H. Sehn, John Raemaekers, John Gribben, Sandra Lockmer, Eva Kimby, Marie José Kersten, Delphine Maucort-Boulch, Bauke Ylstra, Erik van Dijk, Daphne de Jong

Research output: Contribution to journal › Letter › Academic › peer-review

Original language	English
Pages (from-to)	E863
Journal	HemaSphere
Volume	7
Issue number	4
DOIs	https://doi.org/10.1097/HS9.0000000000000863
Publication status	Published - 5 Apr 2023

Access to Document

https://doi.org/10.1097/HS9.0000000000000863

Cite this

Stevens, W. B. C., Los-de Vries, G. T., Langois-Jacques, C., Clear, A. J., Stathi, P., Sander, B., Rosenwald, A., Calaminici, M., Hoster, E., Hiddemann, W., Gaulard, P., Salles, G., Klapper, W., Xerri, L., Burton, C., Tooze, R. M., Smith, A. G., Buske, C., Scott, D. W., ... de Jong, D. (2023). Genetic and Microenvironment Features Do Not Distinguish Follicular Lymphoma Patients Requiring Immediate or Deferred Treatment. HemaSphere, 7(4), E863. https://doi.org/10.1097/HS9.0000000000000863

@article{fe0347884e6944fbbec73a7c5a0103ae,

title = "Genetic and Microenvironment Features Do Not Distinguish Follicular Lymphoma Patients Requiring Immediate or Deferred Treatment",

author = "Stevens, {Wendy B. C.} and {Los-de Vries}, {G. Tjitske} and Carole Langois-Jacques and Clear, {Andrew J.} and Phylicia Stathi and Birgitta Sander and Andreas Rosenwald and Maria Calaminici and Eva Hoster and Wolfgang Hiddemann and Philippe Gaulard and Gilles Salles and Wolfram Klapper and Luc Xerri and Catherine Burton and Tooze, {Reuben M.} and Smith, {Alexandra G.} and Christian Buske and Scott, {David W.} and Yasodha Natkunam and Ranjana Advani and Sehn, {Laurie H.} and John Raemaekers and John Gribben and Sandra Lockmer and Eva Kimby and Kersten, {Marie Jos{\'e}} and Delphine Maucort-Boulch and Bauke Ylstra and {van Dijk}, Erik and {de Jong}, Daphne",

note = "Funding Information: This study was supported by the Dutch Cancer Society grants KWF 2015-7925 and by unrestricted grants from: van Vlissingen Lymfoom Fonds, Genentech/Roche, GlaxoSmithKline, Pfizer Pharma, Teva, Pharmaceuticals/Cephalon, Millennium Pharmaceuticals Inc and Celgene. Haematological Malignancy Research Network is funded by Cancer Research UK, grant numbers 29685; and Blood Cancer UK, grant number 1503. GTLdV, DdJ, BY, and MJK received funding from the Dutch Cancer Society grants KWF 2015-7925. WBCS, EvD, CL-J, and DM-J were funded by unrestricted grants from: van Vlissingen Lymfoom Fonds, Genentech/Roche, GlaxoSmithKline, Pfizer Pharma, Teva, Pharmaceuticals/Cephalon, Millennium Pharmaceuticals Inc and Celgene. AGS was funded by Cancer Research UK and Blood Cancer UK. Funding Information: The Lunenburg Lymphoma Biomarker Consortium, MJK, BY, and DdJ designed the study; WBCS, GTL-dV, EvD, CLJ, AJC, PS performed experiments; WBCS, GTL-dV, EvD, CLJ, BS, AR, DMB, BY, and DdJ analyzed and interpreted the data; WBCS, GTL-dV, EvD, DMB, CLJ, BY, and DdJ wrote the manuscript; and all authors critically revised the manuscript and were involved in its editing and gave final approval of the submitted and published versions. The Lunenburg Lymphoma Biomarker Consortium (LLBC) is a collaboration of 9 international lymphoma research groups, each represented by one or more clinicians and hematopathologists and some also by one or more statisticians. Foundation of the LLBC was made possible with a grant from the van Vlissingen Lymphoma Foundation. EORTC Lymphoma group: Daphne de Jong, John Raemaekers. HOVON Lymphoma group: Daphne de Jong, Marie Jos{\'e} Kersten. LYSA: Philippe Gaulard, Gilles Salles, Luc Xerri. Delphine Maucort-Boulch, Carole Langois-Jacques. British Columbia Cancer Agency: Laurie H. Sehn, David W. Scott. GLA: Andreas Rosenwald, Wolfram Klapper, Christian Buske, Wolfgang Hiddemann, Eva Hoster. Nordic lymphoma group: Birgitta Sander, Eva Kimby. Barts Cancer Institute: Maria Calaminici, John Gribben, Andrew J. Clear. Haematological Malignancy Research Network: Catherine Burton, Reuben M. Tooze, Alexandra G. Smith. Stanford Cancer Institute: Yasodha Natkunam, Ranjana Advani.",

year = "2023",

month = apr,

day = "5",

doi = "https://doi.org/10.1097/HS9.0000000000000863",

language = "English",

volume = "7",

pages = "E863",

journal = "HemaSphere",

issn = "2572-9241",

publisher = "Wolters Kluwer Health",

number = "4",

}

Stevens, WBC, Los-de Vries, GT, Langois-Jacques, C, Clear, AJ, Stathi, P, Sander, B, Rosenwald, A, Calaminici, M, Hoster, E, Hiddemann, W, Gaulard, P, Salles, G, Klapper, W, Xerri, L, Burton, C, Tooze, RM, Smith, AG, Buske, C, Scott, DW, Natkunam, Y, Advani, R, Sehn, LH, Raemaekers, J, Gribben, J, Lockmer, S, Kimby, E, Kersten, MJ, Maucort-Boulch, D, Ylstra, B , van Dijk, E & de Jong, D 2023, 'Genetic and Microenvironment Features Do Not Distinguish Follicular Lymphoma Patients Requiring Immediate or Deferred Treatment', HemaSphere, vol. 7, no. 4, pp. E863. https://doi.org/10.1097/HS9.0000000000000863

TY - JOUR

T1 - Genetic and Microenvironment Features Do Not Distinguish Follicular Lymphoma Patients Requiring Immediate or Deferred Treatment

AU - Stevens, Wendy B. C.

AU - Los-de Vries, G. Tjitske

AU - Langois-Jacques, Carole

AU - Clear, Andrew J.

AU - Stathi, Phylicia

AU - Sander, Birgitta

AU - Rosenwald, Andreas

AU - Calaminici, Maria

AU - Hoster, Eva

AU - Hiddemann, Wolfgang

AU - Gaulard, Philippe

AU - Salles, Gilles

AU - Klapper, Wolfram

AU - Xerri, Luc

AU - Burton, Catherine

AU - Tooze, Reuben M.

AU - Smith, Alexandra G.

AU - Buske, Christian

AU - Scott, David W.

AU - Natkunam, Yasodha

AU - Advani, Ranjana

AU - Sehn, Laurie H.

AU - Raemaekers, John

AU - Gribben, John

AU - Lockmer, Sandra

AU - Kimby, Eva

AU - Kersten, Marie José

AU - Maucort-Boulch, Delphine

AU - Ylstra, Bauke

AU - van Dijk, Erik

AU - de Jong, Daphne

N1 - Funding Information: This study was supported by the Dutch Cancer Society grants KWF 2015-7925 and by unrestricted grants from: van Vlissingen Lymfoom Fonds, Genentech/Roche, GlaxoSmithKline, Pfizer Pharma, Teva, Pharmaceuticals/Cephalon, Millennium Pharmaceuticals Inc and Celgene. Haematological Malignancy Research Network is funded by Cancer Research UK, grant numbers 29685; and Blood Cancer UK, grant number 1503. GTLdV, DdJ, BY, and MJK received funding from the Dutch Cancer Society grants KWF 2015-7925. WBCS, EvD, CL-J, and DM-J were funded by unrestricted grants from: van Vlissingen Lymfoom Fonds, Genentech/Roche, GlaxoSmithKline, Pfizer Pharma, Teva, Pharmaceuticals/Cephalon, Millennium Pharmaceuticals Inc and Celgene. AGS was funded by Cancer Research UK and Blood Cancer UK. Funding Information: The Lunenburg Lymphoma Biomarker Consortium, MJK, BY, and DdJ designed the study; WBCS, GTL-dV, EvD, CLJ, AJC, PS performed experiments; WBCS, GTL-dV, EvD, CLJ, BS, AR, DMB, BY, and DdJ analyzed and interpreted the data; WBCS, GTL-dV, EvD, DMB, CLJ, BY, and DdJ wrote the manuscript; and all authors critically revised the manuscript and were involved in its editing and gave final approval of the submitted and published versions. The Lunenburg Lymphoma Biomarker Consortium (LLBC) is a collaboration of 9 international lymphoma research groups, each represented by one or more clinicians and hematopathologists and some also by one or more statisticians. Foundation of the LLBC was made possible with a grant from the van Vlissingen Lymphoma Foundation. EORTC Lymphoma group: Daphne de Jong, John Raemaekers. HOVON Lymphoma group: Daphne de Jong, Marie José Kersten. LYSA: Philippe Gaulard, Gilles Salles, Luc Xerri. Delphine Maucort-Boulch, Carole Langois-Jacques. British Columbia Cancer Agency: Laurie H. Sehn, David W. Scott. GLA: Andreas Rosenwald, Wolfram Klapper, Christian Buske, Wolfgang Hiddemann, Eva Hoster. Nordic lymphoma group: Birgitta Sander, Eva Kimby. Barts Cancer Institute: Maria Calaminici, John Gribben, Andrew J. Clear. Haematological Malignancy Research Network: Catherine Burton, Reuben M. Tooze, Alexandra G. Smith. Stanford Cancer Institute: Yasodha Natkunam, Ranjana Advani.

PY - 2023/4/5

Y1 - 2023/4/5

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85152207690&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/37038467

UR - http://www.scopus.com/inward/record.url?scp=85152207690&partnerID=8YFLogxK

U2 - https://doi.org/10.1097/HS9.0000000000000863

DO - https://doi.org/10.1097/HS9.0000000000000863

M3 - Letter

C2 - 37038467

SN - 2572-9241

VL - 7

SP - E863

JO - HemaSphere

JF - HemaSphere

IS - 4

ER -

Genetic and Microenvironment Features Do Not Distinguish Follicular Lymphoma Patients Requiring Immediate or Deferred Treatment

Access to Document

Other files and links

Cite this